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Abstract
Background: Frontotemporal lobar degeneration (FTLD) is a devastating and progressive disorder, and a common
cause of early onset dementia. Progranulin (PGRN) haploinsufficiency due to autosomal dominant mutations in the
progranulin gene (GRN) is an important cause of FTLD (FTLD-GRN), and nearly a quarter of these genetic cases are
due to a nonsense mutation. Premature termination codons (PTC) can be therapeutically targeted by compounds
allowing readthrough, and aminoglycoside antibiotics are known to be potent PTC readthrough drugs. Restoring
endogenous PGRN through PTC readthrough has not previously been explored as a therapeutic intervention in
FTLD.
Methods: We studied whether the aminoglycoside G418 could increase PGRN expression in HEK293 and human
induced pluripotent stem cell (hiPSC)-derived neurons bearing the heterozygous S116X, R418X, and R493X
pathogenic GRN nonsense mutations. We further tested a novel substituted phthalimide PTC readthrough enhancer
in combination with G418 in our cellular models. We next generated a homozygous R493X knock-in hiPSC isogenic
line (R493X−/− KI), assessing whether combination treatment in hiPSC-derived neurons and astrocytes could
increase PGRN and ameliorate lysosomal dysfunction relevant to FTLD-GRN. To provide in vivo proof-of-concept of
our approach, we measured brain PGRN after intracerebroventricular administration of G418 in mice expressing the
V5-tagged GRN nonsense mutation R493X.
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Results: The R418X and R493X mutant GRN cell lines responded to PTC readthrough with G418, and treatments
increased PGRN levels in R493X−/− KI hiPSC-derived neurons and astrocytes. Combining G418 with a PTC
readthrough enhancer increased PGRN levels over G418 treatment alone in vitro. PGRN deficiency has been shown
to impair lysosomal function, and the mature form of the lysosomal protease cathepsin D is overexpressed in
R493X−/− KI neurons. Increasing PGRN through G418-mediated PTC readthrough normalized this abnormal
lysosomal phenotype in R493X−/− KI neuronal cultures. A single intracerebroventricular injection of G418 induced
GRN PTC readthrough in 6-week-old AAV-GRN-R493X-V5 mice.
Conclusions: Taken together, our findings suggest that PTC readthrough may be a potential therapeutic strategy
for FTLD caused by GRN nonsense mutations.
Keywords: Progranulin, GRN, Frontotemporal lobar degeneration, Nonsense mutation, Premature termination
codon, Readthrough, G418, Induced pluripotent stem cell, Neurons
Background
Autosomal dominant mutations in the progranulin gene
(GRN) represent a major genetic cause of frontotem-
poral lobar degeneration (FTLD) accounting for 5–10%
of all cases [1–3]. The vast majority of these cases are
due to GRN nonsense mutations, deletions, or splice-site
mutations, leading to progranulin (PGRN) haploinsuffi-
ciency. Since the discovery of PGRN haploinsufficiency
as a major cause of FTLD, there has been an ongoing
search for interventions to raise central nervous system
progranulin as a therapeutic strategy. These strategies
have thus far revolved around non-specific mechanisms
derived from high throughput drug screens as well as
more specific efforts targeting the PGRN signaling path-
way or replacing the protein through adeno-associated
virus (AAV) gene therapy [4–7]. While nearly a quarter
of all GRN linked FTLD (FTLD-GRN) cases are due to a
GRN nonsense mutation [1], to our knowledge suppres-
sion of endogenous nonsense mutations has not been
pursued as a therapeutic strategy despite significant
interest in this approach in other neurologic conditions
[8–10]. Nonsense mutations change an amino acid
codon to a termination codon (UGA, UAG, or UAA)
resulting in the production of a truncated protein and
mRNA destabilization [11]. Several compounds, includ-
ing aminoglycoside antibiotics, can suppress nonsense
mutations by enabling pairing of a near-cognate
aminoacyl-tRNA at a PTC, allowing for the incorpor-
ation of an amino acid instead of termination, leading to
translation of the full-length protein and increased non-
sense mutant mRNA stability [11–13]. However, given
the narrow therapeutic index of aminoglycosides, sup-
plementary compounds that enhance their PTC read-
through activity may allow for lower drug dosing and
thus better tolerability in humans. In a previous study,
we discovered a novel class of aminoglycoside PTC read-
through enhancer compounds (CDX series) using a
high-throughput screen for nonsense suppression in
yeast [14]. We demonstrated that CDX5–1 enhanced
aminoglycoside PTC readthrough by G418 in TP53 non-
sense mutant HDQ-P1 cancer cells [14]. In the present
study, we aimed to investigate whether GRN nonsense
mutations are susceptible to G418-mediated PTC read-
through in preclinical models of FTLD-GRN, including
neurons and astrocytes from patient-derived induced
pluripotent stem cells (iPSCs). We further tested
whether treatment without or with a readthrough en-
hancer could reverse aberrant lysosomal phenotypes pre-
viously described in several preclinical models of FTLD-
GRN as well as neuronal ceroid lipofuscinosis (NCL)
due to progranulin deficiency [15–17]. Our findings pro-
vide proof-of-concept evidence that PTC readthrough is
a promising avenue for therapeutic development for the
treatment of FTLD-GRN patients bearing GRN nonsense
mutations.
Methods
GRN expression vector mutagenesis
Using GeneArt mutagenesis service (Thermo Fisher Sci-
entific) coding sequence of GRN was synthesized and
cloned into pDONR221 Entry vector. Three base substi-
tutions c.347C > A, c.1252C > T and c.1477C > T were
engineered into GRN using a targeted PCR-based strat-
egy to generate S116X (TAA), R418X (TGA) and R493X
(TGA) nonsense mutations. Finally, to generate expres-
sion clones LR recombination reaction was used to re-
combine the mutated samples from the Entry vectors
into the pcDNA-6.2/V5-DEST vector (Thermo Fisher
Scientific). These C-terminal V5 tagged GRN expression
constructs were used for HEK293 cell transfections.
Transfection and generation of stable HEK293 cell lines
HEK293 cells were transiently transfected with
pcDNA6.2/V5-DEST vector expressing C-terminally V5-
tagged mutated GRN with nonsense mutations (S116X,
R418X, R493X) using Lipofectamine 2000 (Thermo
Fisher Scientific). Twenty-four hours after transfection,
each sample was split into two wells and either left
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untreated or treated with G418 (100 μg/mL). After 72 h,
cells were lysed and subjected to automated capillary
electrophoresis western analysis (ProteinSimple WES).
To generate stable cell lines, HEK293 cells were trans-
fected with pcDNA-6.2/V5-DEST vectors expressing
mutant GRN as described above and subjected to blasti-
cidin selection (Thermo Fisher Scientific). Individual
clones that were resistant to 15 μg/mL blasticidin were
selected.
Generation of hiPSCs and neuronal/astrocyte
differentiation
Erythroid progenitor (EP) cells were isolated from per-
ipheral blood obtained from a healthy control subject
(WT) and a GRN R418X mutation carrier (R418X+/−)
[18] using the erythroid progenitor reprogramming kit
(STEMCELL Technologies). Expanded EPs were repro-
grammed into hiPSCs with the Epi5™ episomal repro-
gramming kit (Invitrogen, Thermo Fisher Scientific)
plasmids in Amaxa™ Human CD34+ Cell nucleofection
buffer (Lonza) using the Amaxa™ Nucleofector II (Lonza)
electroporation device according to the erythroid pro-
genitor reprogramming kit manufacturer’s instructions.
hiPSCs were cultured in a feeder-independent manner
on matrigel (BD Biosciences) coated plates and fed daily
with mTeSR1 medium (STEMCELL Technologies).
Every 4–5 days (~ 80% confluence) cultures were pas-
saged as aggregates using ReLeSR (STEMCELL Tech-
nologies) at ~ 1:5 split ratio. During the first 24 h post-
plating, mTeSR1 medium was supplemented with 10 μM
rho-associated protein kinase inhibitor (Y-27632, EMD
Millipore). S116X+/− hiPSCs were obtained from existing
stock and previously described [19].
An isogenic hiPSC line homozygous for GRN R493X
knock-in (R493X−/− KI) was generated from WT using a
combination of previously established CRISPR/Cas9
gene-editing protocols. Guide RNA (gRNA) sequences
were designed according to the Optimized CRISPR De-
sign online tool (http://crispr.mit.edu) to target a region
for double-strand breakage slightly upstream of the GRN
R493 codon. A mutagenizing single-stranded oligo-
nucleotide (ssODN, Integrated DNA Technologies) was
designed to knock-in the R493X mutation and silently
introduce a HindIII restriction enzyme site. hiPSCs were
co-transfected (Lipofectamine Stem Transfection Re-
agent, Invitrogen) with knock-in ssODN and Cas9/
gRNA ribonucleoprotein complexes for 72 h. CRISPR
edited hiPSCs were seeded at clonal density (25 cells /
cm2). Once colonies were of adequate size and morph-
ology, individual colonies were picked and plated for ex-
pansion. Genomic DNA was isolated using QuickExtract
DNA Extraction Solution (Lucigen, Middleton, WI) and
PCR products containing the R493X target site were
digested with HindIII. Clones with positive digestion
signal were selected for Sanger sequencing to confirm
the clean introduction of the R493X KI mutation. Sanger
sequencing was performed by the University of British
Columbia Sequencing + Bioinformatics Consortium.
WT and FTLD-GRN mutant hiPSCs were differentiated
into neuronal progenitor cells (NPCs) using the dual
SMAD inhibition protocol [20]. These NPCs were frozen
and thawed as needed onto matrigel coated plates in neural
stem cell medium for week-long expansion. Expanded
NPCs were then plated onto poly-L-ornithine / laminin
(PLO/L) coated plates and further differentiated into cor-
tical neurons using complete BrainPhys™ (STEMCELL
Technologies) media system [21] supplemented with 1X
CultureOne™ (Gibco, Thermo Fisher Scientific) for the first
2 weeks of neuron maturation. cAMP and ascorbic acid
were withdrawn from BrainPhys™ media after 3 weeks (days
in vitro from hiPSC stage, DIV 50) for continued neuronal
maturation until DIV 80 to allow lysosomal phenotypes to
develop. Astrocytes were differentiated from expanded
cryopreserved NPCs according to the STEMDiff™ astrocyte
differentiation and maturation kit (STEMCELL Technolo-
gies) protocol to produce DIV 60+ frozen stocks to be
thawed and passaged as needed onto matrigel coated plates
in STEMDiff™ astrocyte maturation medium.
Drug administration
G418 sulphate powder was reconstituted in sterile PBS
to 50mg/mL and CDX series compounds in dimethyl
sulfoxide (DMSO) to 50mM. These stock solutions were
stored at − 20 °C. Upon addition of CDX compounds to
cell culture media, gentle vortexing was applied for 2
min to ensure complete solubilization. Vehicle solutions
were prepared by adding corresponding volumes of PBS
and DMSO. Recombinant PGRN (Adipogen, AG-40A-
0068Y-C010) was reconstituted to 0.1 mg/mL in sterile
water. Cathepsin L inhibitor (Z-Phe-Phe-FMK, Abcam,
ab141386) 10 mM stock in DMSO was first diluted to
100 and 300 μM, prior to 1:10 dilution in cell culture
medium. In vivo treatment solutions of vehicle (1.6%
solutol), 16.6 mg/mL G418 (1.6% solutol), 0.5 mM
CDX5–288 (1.6% solutol), and 16.6 mg/mL G418 + 0.5
mM CDX5–288 (1.6% solutol) were prepared in sterile
saline. A 50mM solution of CDX5–288 in DMSO was
first diluted to 3 mM in 10% solutol (diluted in sterile sa-
line) and further diluted 1:6 in treatment solutions.
Chemical synthesis of CDX5–196 and CDX5–288
6-((2,6-dichlorobenzyl)amino)isoindolin-1-one (CDX5–196)
A solution of 6-amino-2, 3-dihydro-1H-isoindol-1-one
(825mg, 1.0 eq), 2,6-dichlorobenzaldehyde (975mg, 1.0 eq)
and AcOH (0.32mL, 1.0 eq) in dichloroethane (56mL) was
treated with NaBH(OAc)3 (1.54 g, 1.3 eq) and stirred at
room temperature for 72 h. Additional aliquots of 2,6-
dichlorobenzaldehyde (488mg, 1.0 eq) and NaBH(OAc)3
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(592mg, 0.5 eq) were added and the reaction was stirred
for a further 24 h. The reaction was then quenched with
saturated aqueous NaHCO3 (50mL) and the layers were
separated. The aqueous layer was extracted with dichloro-
methane (2 × 25mL). The organic layers were combined,
dried over Na2SO4, filtered and concentrated to give the
crude product. This solid was triturated with acetone. Fil-
tration and thorough drying gave CDX5–196 (975mg, 57%
yield) as an off-white solid. 1H NMR (400MHz, DMSO-d6)
δ = 8.35 (s, 1H), 7.53 (d, J = 8.0 Hz, 2H), 7.39 (dd, J = 8.7,
7.4 Hz, 1H), 7.27 (d, J = 8.1Hz, 1H), 6.98–6.92 (m, 2H),
6.04 (t, J = 5.0 Hz, 1H), 4.43 (d, J = 5.0Hz, 2H), 4.21 (s, 2H).
13C NMR (101MHz, DMSO) δ = 171.03, 149.07, 136.14,
134.46, 133.96, 132.10, 130.70, 129.13, 124.19, 117.37,
104.69, 44.74, 43.75.
7-((2,6-dichlorobenzyl)amino)isoquinolin-1(2H)-one (CDX5–
288)
To a mixture of 7-aminoisoquinolin-1(2H)-one (100 mg,
1.0 eq), 2,6-dichlorobenzaldehyde (82 mg, 1.0 eq) and
acetic acid (35 μL, 0.1 eq) in dichloroethane (6 mL) was
added NaBH(OAc)3 (145mg, 1.1 eq). The reaction mix-
ture was stirred at room temperature for 24 h. An add-
itional portion of NaBH(OAc)3 (395 mg, 3.0 eq) was
added and the reaction mixture was stirred for another
24 h. The reaction was quenched with water and the
aqueous layer was extracted with dichloromethane. The
combined organic layers were dried over Na2SO4, fil-
tered and concentrated. Purification via preparative
HPLC (acetonitrile:water with 0.1% trifluoroacetic acid)
afforded CDX5–288 (55 mg, 28% yield) as a light brown
solid. 1H NMR (400MHz, DMSO-d6) δ = 10.94 (d, J =
5.3 Hz, 1H), 7.53 (d, J = 8.1 Hz, 2H), 7.44–7.37 (m, 2H),
7.35 (d, J = 2.5 Hz, 1H), 7.15 (dd, J = 8.6, 2.6 Hz, 1H),
6.87 (dd, J = 7.0, 5.5 Hz, 1H), 6.39 (d, J = 7.0 Hz, 1H),
6.23 (s, 1H), 4.47 (d, J = 4.8 Hz, 2H). 13C NMR (101
MHz, DMSO-d6) δ = 162.12, 147.81, 136.18, 134.30,
130.74, 129.11, 128.76, 127.96, 127.50, 124.43, 120.80,
105.38, 105.17, 43.52.
Antibodies
The antibodies used in this study were NANOG (R&D
Systems, AF1997, 1:500), OCT4 (STEMCELL Technolo-
gies, 60093, 1:1000), SOX1 (STEMCELL Technologies,
60095, 1:1000), SOX17 (R&D Systems, AF1924, 1:500),
DESMIN (Invitrogen, PA5–16705, 1:500), MAP2 (Pro-
teintech, 17490–1-AP, 1:500), TUJ1 (Neuromics,
CH23005, 1:500), GFAP (STEMCELL Technologies,
60128, 1:500), TBR1 (Abcam, ab31940, 1:500), FOXG1
(Abcam, ab18259, 1:500), SYNAPSIN (EMD Millipore,
5747777, 1:500), VGLUT1 (Synaptic Systems, 135311, 1:
500), GAD 65/67 (Sigma-Aldrich, G5163, 1:500), PGRN
(R&D Systems, AF2420, 1:1000) (for immunofluores-
cence); PGRN (Sigma-Aldrich, HPA008763, 1:1000),
CTSD (R&D Systems, AF1014, 1:1000), ACTIN (Novus
Biologicals, NB600–532, 1:10,000) (for conventional
western blot); V5 (Abcam, ab27671, 1:500), ACTIN
(Novus Biologicals, NB600–532, 1:10,000) (for auto-
mated WES western blot) (Table S1).
Brightfield microscopy
Live cultures were photographed with a digital camera
mounted to a tissue culture microscope (40X obj. lens)
throughout the differentiation process from hiPSCs to
cortical neurons.
Immunofluorescence microscopy
Cells were fixed with 4% paraformaldehyde (PFA) for 15
min and washed three times with Dulbecco phosphate-
buffered saline (D-PBS, Gibco, Thermo Fisher Scientific).
Cells were blocked and permeabilized with 10% donkey
or goat serum (Sigma-Aldrich) in D-PBS containing
0.1% triton X-100 (Abcam) for 1 h at room temperature
(RT). Primary antibodies were then diluted (see Anti-
bodies Methods section or Table S1) in 10% donkey or
goat serum in D-PBS and applied to cells overnight at
4 °C. all Alexa Fluor-tagged secondary antibodies (Invi-
trogen, Thermo Fisher Scientific) were used at a dilution
of 1:500 at RT for 2 h. the coverslips were then mounted
in DAPI mounting medium (Vector Laboratories). Im-
ages were captured with ZEN 2 software using a Zeiss
880 scanning laser confocal microscope. Image quantifi-
cation was performed with NIH ImageJ. The % of neu-
rons expressing specific markers were determined by
applying uniform thresholds and converting images to
binary using watershed segmentation tool and quantify-
ing the number of individual DAPI+/neuronal marker+
cells with the analyze particles function. Cytotoxicity
was assayed by staining fixed (as above) 96-well
plate neuronal cultures with Hoechst dye (1.5 μg/mL,
H3570, Invitrogen). These plates were imaged using a
Cellomics ArrayScan™ plate scanner (Thermo Fisher Sci-
entific) and the number of cells were automatically
counted with acQuisition™ software (Thermo Fisher
Scientific).
Multielectrode array electrophysiology
WT and mutant hiPSC-derived NPCs (DIV 30) were co-
cultured with hiPSC-derived WT astrocytes (DIV 60+)
in 1:1 ratio and plated onto 48-well multielectrode array
(MEA) plates (Axion BioSystems) coated with PLO/L.
Cells were plated using drop seed method, where 15 μL
of mixed cell suspension (60,000 cells in total) in a 10%
dilution of matrigel in BrainPhys™ + 1X Culture-
One™ media was pipetted onto the electrode array in the
center of each well. The cultures were fed by partial
media replacement every 3 days according to our neur-
onal differentiation protocol stated above. Spontaneous
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electrophysiological activity of the neuron-astrocyte co-
cultures was recorded for 10 min at cortical neuron DIV
50 using the Axion biosystems maestro MEA at 37 °C
and 5% CO2. Data analysis was performed using AxIs
software (Axion BioSystems) to extract the number of
spikes and bursts from the recording file. Quality criteria
for the assays were defined as follows: an electrode hav-
ing an average of more than 5 spikes/min and wells with
less than 30% of the total electrodes active were consid-
ered inactive and excluded from the analysis.
Conventional western blot
Cortical neuron and astrocyte supernatant were col-
lected, and cell monolayers were rinsed with 1 mL ice-
cold PBS. Cells were lysed in 50 μl lysis buffer (20 mM
Tris–HCl pH 7.5, 150mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% (v/v) triton X-100, 2.5 mM sodium pyrophos-
phate, 1 mM β-glycerophosphate) supplemented with
fresh 1 mM Na3VO4, and 1X complete protease inhibitor
cocktail (Roche Molecular Biochemicals). Lysates and
supernatants were pre-cleared by centrifugation at 14,
000 rpm (19,500 x g) for 10 min at 4 °C. lysate protein
concentration was quantitated using the Bradford assay.
In brief, 10–30 μg protein from each boiled SDS lysate
was separated on 4–15% gradient precast polyacrylamide
gel (Bio-Rad Laboratories), electroblotted onto a nitro-
cellulose membrane and blocked for 1 h in 5% (w/v)
non-fat milk. Membranes were incubated with primary
antibodies overnight at 4 °C, washed three times with
TBS + 0.1% (v/v) Tween-20 (TBS-T), incubated with
HRP-conjugated secondary antibody, washed again 3X
with TBS-T and incubated with enhanced chemilumin-
escence substrate (EMD Millipore). Films were devel-
oped, scanned, and analyzed using NIH ImageJ for
densitometry analysis.
ProteinSimple WES analysis
Automated capillary electrophoresis western analysis
was carried out with manufacturer’s reagents according
to the user manual (ProteinSimple WES). HEK293 cell
lysates were prepared following the method used for
neurons/astrocytes and AAV brain lysates were prepared
according to brain tissue lysate preparation method sec-
tion. Briefly, 5.6 μl of 1 mg/mL HEK293 cell/brain lysate
was mixed with 1.4 μl fluorescent master mix and heated
at 95 °C for 5 min. The samples, blocking reagent, wash
buffer, primary antibody, secondary antibody, and
chemiluminescent substrate were dispensed into the mi-
croplate provided by the manufacturer. The electrophor-
etic separation and immunodetection were performed
automatically using the WES instrument default settings.
PGRN was quantified using size-based detection with
the integrated compass software (ProteinSimple). The
full-length V5 (PGRN) peak intensities (area under the
curve) were normalized to that of the actin peak, used as
a loading control. In Fig. 1 and Fig. 8 electropherograms
are represented as pseudo-blots, generated from the
quantification of chemiluminescence by the compass
software.
Progranulin ELISA
Progranulin levels in neuronal and astrocyte whole cell
lysates (as prepared for western blot) and concentrated
supernatants (Amicon Ultra 0.5 mL, 50 kDa, 25X con-
centrated) were determined by ELISA (Adipogen) using
the manufacturer’s protocol. Cultures were treated with
an equal volume of media and an equal volume of super-
natant was concentrated for each sample. Neuronal and
astrocyte lysates (1 mg/mL) and concentrated super-
natant were diluted in ELISA buffer as specified.
qPCR
Total RNA was extracted from hiPSC, cortical neurons, and
astrocytes using RNeasy Plus Mini Kit (Qiagen). cDNA was
produced by reverse transcription using the High-Capacity
RNA-to-cDNA Kit (Applied Biosystems, Thermo Fisher Sci-
entific). To measure the endogenous gene expression of
pluripotency factors and neuronal/astrocyte GRN, the qPCR
analysis was performed using the 7900HT Fast Real-Time
PCR System (Applied Biosystems, Thermo Fisher Scientific).
mRNA was detected with Taqman probes (Thermo Fisher
Scientific, OCT4 Hs01895061_u1, LIN28 Hs00702808_s1,
NANOG Hs02387400_g1, SOX2 Hs00602736_s1, GRN
Hs00963707_g1, HPRT1 Hs02800695_m1, and GAPDH
Hs03929097_g1) in combination with the Taqman Univer-
sal PCR Master Mix (Applied Biosystems, Thermo Fisher
Scientific). Gene expression of hiPSC markers was normal-
ized to GAPDH housekeeping gene and compared to hu-
man fibroblast expression using the ΔΔCt-method. GRN
gene expression in cortical neurons and astrocytes was nor-
malized to the mean of GAPDH and HPRT1 housekeeping
genes and compared to vehicle-treated WT expression using
the ΔΔCt-method.
Trilineage differentiation
hiPSCs were differentiated into the three germ layers
using the StemDiff™ Trilineage Differentiation Kit
(STEMCELL Technologies) according to manufacturer’s
instructions. After differentiation, cells were fixed in 4%
PFA for 15 min for immunofluorescence analysis with
anti-SOX1 (ectoderm), anti-SOX17 (endoderm), and
anti-DESMIN (mesoderm) antibodies.
AAV construct production and injections
The packaging of AAV-GRN-R493X-V5 was performed
by the Petrucelli group at Mayo Clinic Jacksonville. The
coding sequence for GRN V5-tagged R493X was cloned
into the AAV expression vector pAM/CBA-EGFP-
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WPRE-BGH, AAV particles were packaged into serotype
9 capsid, and purified using standard methods [22].
Briefly, AAV was generated by co-transfection with the
cis plasmids pF Delta6 and pRepCap9 into HEK293T
cells. Cells were harvested 72 h after transfection, treated
with 50 Units/ml Benzonase (Sigma-Aldrich), and lysed
by freeze thaw. The virus (AAV-GRN-R493X-V5) was
then purified using a discontinuous iodixanol gradient
and buffer exchanged to PBS using an Amicon Ultra 100
Centrifugation device (EMD Millipore). The genomic
titer of each virus was determined by quantitative PCR
using the ABI 7700 (Applied Biosystems) and primers
specific to the WPRE. The viral DNA samples were pre-
pared for quantification by treating the virus with DNa-
seI (Invitrogen) and Proteinase K (Invitrogen), and
samples were compared against a standard curve of
supercoiled plasmid. AAV9-eGFP-Cre viral particles
(AddGene, 105540-AAV9) were used to demonstrate
technical proficiency through the detection of brain-
wide human synapsin promoter driven eGFP expression
Fig. 1 Induction of PTC readthrough by G418 and CDX5 enhancers in cells expressing GRN-V5. a Schematic of full-length PGRN highlighting the
position of the S116X (UAA), R418X (UGA), and R493X (UGA) nonsense mutations in relation to the position of individual granulin peptides and
the C-terminal V5 tag. b HEK293 cell lines stably expressing GRN-V5 with the indicated nonsense mutations were treated with G418 and the
indicated concentrations of CDX5–1, CDX5–196, and CDX5–288 for 72 h. Cell culture supernatants (extracellular) and cell lysates (intracellular)
were subjected to automated capillary electrophoresis western analysis. Full-length PGRN was detected with a V5 antibody. Actin was measured
in cell lysates as a loading control. The readthrough enhancement ratios are indicated under the lanes. The proportion loaded was 15–20 fold
lower for the extracellular samples than for the intracellular samples
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in 10-week-old AAV9-eGFP-Cre mice. On the day of
birth (P0), C57BL/6 neonates were anesthetized using
isoflurane and bilaterally injected intracerebroventricu-
larly with 0.5 μL of viral vector (AAV-GRN-R493X-V5 =
8E13 pfu/mL and AAV9-eGFP-Cre = 1E13 pfu/mL)
through a finely drawn glass micropipette as described
previously [23]. PTC readthrough treatment was per-
formed when AAV-GRN-R493X-V5 mice were 6 weeks
old.
Surgical procedures
A single intracerebroventricular (ICV) bolus injection of
vehicle, CDX5–288, or G418 ± CDX5–288 was per-
formed in 6-week-old AAV-GRN-R493X-V5 mice ac-
cording to previously published works with some
modifications [24]. Mice lateral ventricles were injected
stereotactically (3 μL volume, coordinates: − 1.0 mm lat-
eral/− 0.3 mm posterior/− 3.0 mm depth to bregma) by
loading a glass micropipette needle attached to a micro-
syringe pump to deliver the dosage at a flow rate of
1 μL/min. Following drug injection, the needle was left
in place for 3 min and then removed at a rate of 1 mm/
second while holding a cotton swab against the skull at
the base of the needle. The incision was then sutured
with monocryl sutures (Ethicon, J303H) to close the
skin. The mice were placed on the heating pad warmed
half of a cage to ensure the mice were kept at 36–38 °C
for the first 1.5 h while they recovered from the
anesthesia, with the option for them to move away from
the heat. After mice had recovered fully from surgery,
they were transferred to the mouse housing room. 5mg/
kg meloxicam was injected subcutaneously once per day
for the first 2 days following surgery.
Brain collection and lysis
Seventy-two hours following ICV vehicle/drug injection,
mice were perfused with PBS before brain collection.
Brains were immediately flash frozen on dry ice. Whole
brains were later thawed, homogenized in 500 μL TBS
lysis buffer (150 mM NaCl, 1 mM EDTA, 1 mM sodium
orthovanadate, 1 mM NaF, 1 mM β-glycerophosphate,
2.5 mM sodium pyrophosphate, 1 mM PMSF, Phos-
STOP, cOmplete mini), sonicated for 10 s at 20% ampli-
tude and ultracentrifuged at 100,000 x g for 20 min at
4 °C. The supernatants were collected as TBS-soluble ex-
tract, and the pellets were homogenized in RIPA buffer
(TBS lysis buffer + 1% NP-40), sonicated, and again
ultracentrifuged at 100,000 x g for 20 min at 4 °C. The
supernatants were collected as RIPA-soluble extract.
The protein concentration of RIPA-soluble fractions was
measured by Bradford, diluted to 1 mg/mL and assayed
by V5 WES analysis to detect AAV-GRN-R493X-V5
PTC readthrough products.
Karyotyping analysis
Karyotyping was performed on WT, R418X+/−, &
R493X−/− KI by WiCell Cytogenetics, Inc. (Madison,
WI). The S116X+/− line was previously karyotyped by
Cell Line Genetics (Madison, WI) following the produc-
tion of this line [19].
Statistical analysis
All values are expressed as the mean ± SEM. In experi-
ments where two groups were compared a standard un-
paired two-tailed Student’s t-test was performed to
measure significance. For comparisons of more than two
groups, one-way analysis of variance (ANOVA) was used
followed by Tukey’s comparison post hoc test. P-values
less than 0.05 were considered significant. Statistical
analysis was performed using GraphPad Prism Software,
Version 5.0.
Results
G418 combined with CDX5–288 maximizes GRN PTC
readthrough in HEK293 cells
The efficiency of PTC readthrough is affected by the
specific nonsense codon sequence and the flanking nu-
cleotide sequences [25, 26]. Therefore, to survey the re-
sponsiveness of GRN nonsense mutations to PTC
readthrough we designed several clinical GRN nonsense
mutation expression constructs. We first transiently
transfected HEK293 cells with S116X (UAA), R418X
(UGA), and R493X (UGA) C-terminally V5-tagged ex-
pression constructs (Fig. 1a) and treated them for 72 h
with the aminoglycoside G418. Mock transfected
HEK293 cells showed no detectable V5 signal (Fig. S1).
Since the V5 tag was inserted at the C-terminus, any V5
detected represented full-length PGRN generated by
PTC readthrough. G418 induced GRN PTC readthrough
in cells with the R418X and R493X mutations, with V5
(full-length PGRN) detected in both the cell lysate
(intracellular) and supernatant (extracellular) fractions
(Fig. S1). The accumulation of full-length PGRN in both
the intra- and extracellular fractions of transiently trans-
fected HEK293 cells suggests that the PGRN read-
through product retains its ability to be post-
translationally processed via the secretory pathway. The
S116X mutant did not respond to G418 treatment
(Fig. S1), and this may be because aminoglycoside-
induced PTC readthrough is most efficient at UGA
nonsense codons and least efficient at UAA nonsense
codons (UGA > UAG > UAA) [25].
To further screen and validate the GRN PTC read-
through observed in transiently transfected cells, we gen-
erated HEK293 lines stably expressing GRN-V5
nonsense mutant constructs. When treated with G418
these cell lines exhibited a similar GRN PTC read-
through response to that observed in transiently
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transfected cells (Fig. 1b). Stable GRN-V5 expressing
HEK293 lines provided an ideal screening platform to
test which compounds could most effectively enhance
G418-induced GRN PTC readthrough. We treated
HEK293 cell lines expressing nonsense mutant GRN-V5
with G418 without or with readthrough enhancers
CDX5–1 [14], CDX5–196 (Fig. S2a), or CDX5–288 (Fig.
S2b) for 72 h, and measured intra- and extracellular V5
levels. CDX5 compounds enhanced G418-induced PTC
readthrough activity in both the R418X and R493X mu-
tant lines and full-length PGRN was detected in both
the intra- and extracellular fractions (Fig. 1b). CDX5–
288 produced the highest enhancement of readthrough
activity (Fig. 1b). Thus, co-treatment with G418 and
CDX5–288 was selected for further validation in patient
hiPSC-derived cortical neurons and astrocytes and an
AAV mouse model.
FTLD-GRN patient hiPSC-derived cortical neurons and
astrocytes show increased PGRN levels in response to PTC
readthrough treatment
Next, we sought to determine whether treatment with
G418 alone or in combination with CDX5–288 could
rescue PGRN deficiency in more clinically relevant cell
types with GRN heterozygosity or nullizygosity caused
by nonsense mutations. An hiPSC line produced from
an FTD-GRN patient bearing the g.585 C > A (S116X)
GRN nonsense mutation (designated S116X+/−) was ob-
tained from our stock [19]. Additionally, we generated
hiPSC lines from one healthy control (designated WT)
and an FTD-GRN patient carrying the g.2923 C > T
(R418X) GRN nonsense mutation (designated R418X+/−)
[18, 27]. We then used CRISPR/Cas9 gene-editing to
generate from WT an isogenic clone homozygous for
the most common FTD-GRN mutation g.3240 C > T
(R493X) (designated R493X−/− KI) (Fig. S3a-c). To
characterize the hiPSC lines we assessed their expression
of pluripotent markers at the protein and mRNA level,
their ability to differentiate into all three germ layers,
and demonstrated that they were all karyotypically nor-
mal (Fig. S4a,b).
We then differentiated the hiPSC lines into cortical
neurons using a recently reported version of the dual
SMAD inhibition neuroectoderm induction protocol
[20] in combination with BrainPhys™ medium NPC
neuronal maturation [21] (Fig. 2a). The resulting neur-
onal cultures possessed high levels of purity, as indicated
by high percentage of MAP2 positive (> 95%) and low
percentage of GFAP positive cells (< 4%) (Fig. 2b-d).
Additionally, greater than 75% of cells expressed both
FOXG1 and TBR1 confirming these neurons express
cortical layer VI markers (Fig. 2b, e, f). Synaptogenesis
was demonstrated in these cultures by staining for ana-
lysis of the expression of synapsin and excitatory/
inhibitory synaptic markers (Fig. S5a, b). Astrocytes were
also differentiated from NPCs using an astrocyte differ-
entiation/maturation kit protocol. Mature astrocyte cul-
tures (DIV 60+) derived from both WT and R493X−/−
KI hiPSC lines both expressed high levels (80%) of GFAP
(Fig. 2g, h). Co-culturing neurons with WT human as-
trocytes on MEA plates led to the maturation of electro-
physiologically active neurons and the formation of
neural networks with frequent and robust spontaneous
action potentials measured by MEA electrophysiology
(Fig. S5c).
hiPSC-derived cortical neurons were matured to DIV 50
and exposed to PTC readthrough compounds for 72 h.
The levels of WT neuronal full-length PGRN expression
were not sufficiently high for detection by western blotting
with available anti-PGRN antibodies (Fig. S6, S7). As an
alternative, intracellular and concentrated extracellular
fractions were assayed by ELISA using a PGRN polyclonal
antibody to multiple epitopes (GRN 1/3/5/7 peptides) that
detects not only full-length PGRN but also truncated
PGRN as well as granulin (GRN) peptides, collectively re-
ferred to here as PGRN/GRNs. Vehicle-treated S116X+/−,
R418X+/−, and R493X−/− KI neurons expressed 33.1% ±
1.5, 49.9% ± 1.3, and 74.5% ± 1.2% less intracellular
PGRN/GRNs than vehicle-treated WT neurons, as ex-
pected (Fig. 3, S8). In general, treatment of FTLD-GRN
mutant neurons with G418 without or with CDX5–288
produced a similar pattern of PGRN/GRNs expression to
that observed in the stably transfected HEK293 cell lines
bearing the same mutations. Again, the S116X+/− neurons
exhibited little to no intra- or extracellular increase in the
levels of PGRN/GRNs in response to PTC readthrough
treatment (Fig. 3a, e). R418X+/− neurons exposed to G418
alone or to G418 and CDX5–288 showed significantly in-
creased intracellular PGRN/GRNs levels to 67.5% ± 1.2
and 75.8% ± 5.8% of vehicle-treated WT levels, respect-
ively (Fig. 3b). Treatment of R493X−/− KI neurons with
G418 alone significantly increased intracellular PGRN/
GRNs levels, to 54.0% ± 5.5% of vehicle-treated WT levels
and exposure to G418 and CDX5–288 further signifi-
cantly increased intracellular PGRN/GRNs levels com-
pared G418 alone, to 83.9% ± 1.3% of vehicle-treated WT
(Fig. 3c). For both R418X+/− neurons and R493X−/− KI
neurons, extracellular PGRN/GRNs levels were not sig-
nificantly increased in response to treatment although a
trend toward a minor increase was observed (Fig. 3f, g).
Since R493X−/− KI neurons have no WT GRN allele, the
observed increase in intracellular PGRN/GRNs is likely
due to expression of the mutated allele. G418 did not
show significant cellular toxicity in iPSC-derived neurons
(Fig. S9).
Contrary to expectation, we observed that WT cortical
neurons treated with G418 alone and in combination with
CDX5–288 showed significantly increased intracellular
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Fig. 2 (See legend on next page.)
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PGRN/GRNs levels relative to vehicle-treated cells, by
37.9% ± 3.2 and 42.9% ± 3.7, respectively (Fig. 3d). This
intracellular increase in WT neuronal PGRN/GRNs levels
was not due to PTC readthrough as both GRN alleles are
WT. CDX5–288 alone did not increase intracellular WT
neuronal PGRN/GRNs and its combination with G418
did not increase PGRN/GRNs over G418 treatment alone,
indicating the observed increase is mediated by G418 (Fig.
3d). The G418-mediated increase in intracellular WT
neuronal PGRN/GRNs expression was not accompanied
by a corresponding increase in PGRN/GRNs secretion
(Fig. 3h). These findings in WT neurons suggest G418
may disrupt PGRN exocytosis. The potential mechanisms
driving this phenomenon are addressed in more detail in
the context of WT astrocytes (Fig. 5, 6b).
Next, WT and R493X−/− KI hiPSC-derived astrocytes
were matured to DIV 60+ to extend testing of read-
through compounds to another relevant CNS cell type
with endogenous nonsense mutant GRN expression. WT
hiPSC-derived astrocytes produced 17.9-fold more intra-
cellular PGRN/GRNs, secreted 25.0-fold more PGRN/
GRNs, and expressed 3.7-fold higher GRN mRNA than
WT hiPSC-derived neurons as measured by ELISA and
qPCR (Fig. S6). This considerably higher expression level
enabled analysis of intracellular PGRN levels by western
blotting in hiPSC-derived astrocyte cultures (Fig. 4). The
PGRN antibody used in this western blot analysis has
previously been shown to detect full-length PGRN as
well as GRN peptides (GRN-2,3) [28]. In WT astrocytes,
both PGRN and GRN-2,3 peptides were detected,
though the GRN-2,3 peptides were more abundant than
full-length PGRN (Fig. 4a). R493X−/− KI astrocytes
expressed small amounts of a band at ~ 70 kDa that may
be PGRN truncated at R493, and no detectable GRN-2,3
peptides (Fig. 4a). Treating R493X−/− KI astrocytes with
either G418 alone or G418 and CDX5–288 significantly
increased intracellular ~ 70 kDa PGRN, by 3.3- and 4.6-
fold, respectively (Fig. 4a, b.i). This increase in intracellu-
lar ~ 70 kDa PGRN was accompanied by a small increase
in GRN-2,3 peptide signal, which indicates that at least
some of the protein entered lysosomes and was cleaved
into individual GRN peptides (Fig. 4a, b.ii). Exposing
R493X−/− KI astrocytes to extracellular recombinant
human PGRN showed that these cells can take up and
process PGRN, as the vast majority of endocytosed full-
length PGRN was converted into GRN peptides (Fig. 4a, b).
Since the rate of conversion of full-length PGRN to GRN-2,
3 peptides is so efficient in astrocytes, we hypothesized that
full-length PGRN generated by readthrough would be rap-
idly processed into GRN peptides, perhaps explaining why
we observe limited full-length PGRN in G418 and CDX5–
288 combination-treated R493X−/− KI astrocytes. The lyso-
somal cysteine protease cathepsin L cleaves PGRN into
GRN peptides [29]. Therefore, we tested whether inhibiting
cathepsin L during G418 and CDX5–288 induced PTC
readthrough in R493X−/− KI astrocytes could enable clear
visualization of full-length PGRN by western blot. Co-
treating R493X−/− KI astrocytes with 30 μM Z-Phe-Phe-
FMK (Cathepsin L inhibitor), G418 and CDX5–288 led to
significant accumulation of PTC readthrough derived full-
length PGRN (Fig. 4c, d), confirming our hypothesis.
We next used ELISA to measure of intra- and extra-
cellular PGRN/GRNs levels in astrocytes. Vehicle-
treated R493X−/− KI astrocytes expressed 81.8% ± 1.6%
less intracellular PGRN/GRNs than vehicle-treated WT
astrocytes (Fig. 5a, b). R493X−/− KI astrocytes exposed to
G418 alone or G418 and CDX5–288 showed signifi-
cantly increased intracellular PGRN/GRNs levels, to
75.7% ± 6.5 and 75.8% ± 3.2%, respectively, of vehicle-
treated WT levels, only slightly less than PGRN/GRNs
restoration achieved through the application of exogen-
ous recombinant human PGRN (Fig. 5b). Vehicle-
treated R493X−/− KI astrocytes secreted 94.9% ± 0.3%
less PGRN/GRNs than vehicle-treated WT astrocytes
(Fig. 5c, d). Exposure to G418 alone or G418 and
CDX5–288 caused a considerable increase in secreted
PGRN/GRNs, to 30.4% ± 1.7 and 32.5% ± 1.2%, respect-
ively, of vehicle-treated WT levels (Fig. 5c, d), unlike
R493X−/− KI cortical neurons, where treatment in-
creased intracellular PGRN/GRNs but only subtly in-
creased PGRN/GRNs secretion. G418 increased
intracellular PGRN/GRNs in WT astrocytes by
31.7% ± 5.6%, without a corresponding increase in se-
creted PGRN/GRNs (Fig. 5a, c), as was observed with
WT cortical neurons. Western blotting revealed that
G418 significantly increased the intracellular levels of
(See figure on previous page.)
Fig. 2 Differentiation and characterization of human cortical neurons and astrocytes derived from FTD-GRN patient and control hiPSCs. a
Brightfield images of the cells at different stages of cortical neuronal differentiation. SB = SB 431542, LDN = LDN 193189, RI = Y-27632, BP =
BrainPhys™, N2 = N-2 supplement, B27 = B-27 supplement. b Representative immunofluorescence images of DIV 50 WT, S116X+/−, R418X+/−, and
R493X−/− KI hiPSC-derived cortical neurons stained for MAP2, GFAP, TUJ1, FOXG1 (forebrain), and TBR1 (cortical layer VI). Cell nuclei were
counterstained with DAPI (blue). Scale bar, 50 μm. c-f Cells positive for MAP2, GFAP, FOXG1, and TBR1 (neuronal, astrocytes, forebrain, and cortical
layer VI markers, respectively) as a percentage of DAPI+ cells. On average, ~ 900 cells were analyzed per replicate, in (c-f) n = 3 independent
cultures, 3 images per biological replicate; values are shown as mean ± SEM. g Representative immunofluorescence images of DIV 60+ WT and
R493X−/− KI hiPSC-derived astrocytes stained for GFAP. Cell nuclei were counterstained with DAPI (blue). Scale bar, 50 μm. h Cells positive for
GFAP as a percentage of DAPI+ cells. On average, ~ 400 cells were analyzed per replicate, n = 3 independent cultures, 3 images per biological
replicate; values are shown as mean ± SEM
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PGRN while decreasing the levels of GRN-2,3 peptides
in WT astrocytes (Fig. S10). Therefore, G418 may dis-
rupt the normally highly efficient lysosomal processing
of full-length PGRN to GRN peptides in astrocytes. To
further probe the mechanism of this unanticipated
readthrough-independent increase in WT intracellular
PGRN, we conducted GRN qPCR analysis in WT hiPSC-
derived neurons and astrocytes. Treating WT neurons
or astrocytes with G418 alone or in combination with
CDX5–288 did not significantly increase GRN mRNA
Fig. 3 Induction of PTC readthrough by G418 and enhancers in hiPSC-derived cortical neurons bearing FTD-GRN nonsense mutations. DIV 50
S116X+/−, R418X+/−, R493X−/− KI, and WT hiPSC-derived cortical neurons were treated with G418 and CDX5–288 at the indicated concentrations
for 72 h. Intracellular (a-d, 1 mg/mL lysate) and extracellular (e-h, 25X concentrated supernatant) samples were subjected to PGRN ELISA using a
polyclonal anti-PGRN antibody that targets multiple epitopes (GRN 1/3/5/7 peptides) and cannot differentiate between truncated/full-length
PGRN or GRN peptides (PGRN/GRNs). n = 3 independent cultures; values are shown as mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.0001 was
determined by one-way ANOVA with Tukey’s multiple comparison test
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Fig. 4 Induction of PTC readthrough by G418 and enhancers in hiPSC-derived R493X−/− KI astrocytes. a R493X−/− KI hiPSC-derived astrocytes
were treated with vehicle solution, G418 alone, G418 in combination with CDX5–288, and rec. Human PGRN at the indicated concentrations for
72 h. Expression of PGRN and GRN-2,3 peptides in treated WT and R493X−/− KI astrocyte samples were analyzed by western blotting, using actin
as the loading control. b Densitometric quantification of ~ 70 kDa PGRN (i) and GRN-2,3 peptide (ii) in astrocyte lysates (a) normalized to vehicle-
treated (VT) WT levels. VT WT was excluded from ii due to oversaturation of GRN-2,3 signal in long exposure blot. For clarity, rec. Human PGRN
treated R493X−/− KI astrocytes expressed 20.9% ± 0.027 of VT WT GRN-2,3 levels based on quantification of the short exposure blot (data not
shown). c R493X−/− KI hiPSC-derived astrocytes were treated with vehicle solution, G418 in combination with CDX5–288, and G418 CDX5–288
combination with either 10 or 30 μM of Z-Phe-Phe-FMK for 72 h. Again, expression of PGRN in WT and R493X−/− KI astrocyte lysates was also
analyzed by western blotting, using actin as the loading control. d Densitometric quantification of full-length PGRN in astrocyte lysates (c)
normalized to VT WT levels. n = 3 independent cultures (except in d n = 2); values are shown as mean ± SEM; p < 0.05, ** p < 0.01, *** p < 0.0001
was determined by one-way ANOVA with Tukey’s multiple comparison test
Frew et al. Molecular Neurodegeneration           (2020) 15:21 Page 12 of 19
Fig. 5 Induction of PTC readthrough by G418 and enhancers in R493X−/− KI hiPSC-derived astrocytes. DIV 60+ WT and R493X−/− KI hiPSC-derived
astrocytes were treated with G418, CDX5–288, and rec. Human PGRN at the indicated concentrations for 72 h. Intracellular (a-b, 1 mg/mL lysate)
and extracellular (c-d, 25X concentrated supernatant) samples were subjected to PGRN ELISA using a polyclonal anti-PGRN antibody that targets
multiple epitopes (GRN 1/3/5/7 peptides). Therefore, the antibody cannot differentiate between truncated/full-length PGRN or GRN peptides
(PGRN/GRNs). n = 3 independent cultures; values are shown as mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.0001 was determined by one-way
ANOVA with Tukey’s multiple comparison test
Fig. 6 Selective increase of R493X−/− KI nonsense mutant mRNA by PTC readthrough treatment. qPCR analysis of human GRN mRNA levels in DIV
50 WT and R493X−/− KI hiPSC-derived cortical neurons (a) and DIV60+ astrocytes (b) treated with G418 and CDX5–288 at the indicated
concentrations for 72 h. Relative GRN mRNA levels were normalized to the mean of GAPDH and HPRT1 housekeeping genes and compared to
vehicle-treated (VT) WT. n = 3 independent cultures; values are shown as mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.0001 was determined by
one-way ANOVA with Tukey’s multiple comparison test
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levels (Fig. 6a, b). We speculate that G418 affects PGRN
homeostasis at the protein level resulting in reduced
lysosomal processing of full-length PGRN into individual
GRN peptides.
qPCR analysis revealed that readthrough compounds
caused a strong increase in GRN mRNA levels in
R493X−/− KI neurons and astrocytes, in contrast to WT
cells. This was an anticipated observation as mRNAs
bearing nonsense mutations are targeted for degradation
by nonsense-mediated mRNA decay (NMD) [30] and
PTC readthrough enables escape of nonsense mutant
mRNA from degradation by NMD. Vehicle-treated
R493X−/− KI neurons expressed 5.1-fold less GRN
mRNA relative to vehicle-treated WT neurons (Fig. 6a),
and vehicle-treated R493X−/− KI astrocytes expressed
3.3-fold less GRN mRNA than vehicle-treated WT astro-
cytes (Fig. 6b), indicating downregulation of mutant
mRNA by NMD. When treated with G418 or combin-
ation, R493X−/− KI neurons and astrocytes showed large
increases in GRN mRNA (Fig. 6a, b). The selective
stabilization of PTC-bearing GRN mRNA over WT GRN
mRNA strongly supports inhibition of NMD consequent
to readthrough in R493X−/− KI neurons and astrocytes.
Taken together these results show that the G418 -
CDX5–288 combination induces PTC readthrough and
effectively restores intracellular levels of PGRN in both
heterozygous and homozygous GRN nonsense mutant
neurons and astrocytes to levels approaching that of
healthy control cells, while also revealing that G418 can
interfere with intracellular PGRN processing.
Restoration of PGRN levels by PTC readthrough rescues
lysosomal dysfunction in FTD-R493X−/− KI hiPSC-derived
cortical neurons
The specific nonsense mutant codon (ex: R493X−/− KI,
Arg-CGA to X-UGA) restricts which near-cognate
aminoacyl-tRNA molecules (Trp UGG, Cys UGC, Arg
CGA, etc.) pair with the PTC in the ribosome A site and
contribute their amino acid to the growing polypeptide
during a readthrough event. Previous studies have dem-
onstrated that the amino acids most commonly incorpo-
rated at UGA nonsense mutations during readthrough
were Trp, followed by Cys and Arg [31]. Thus, it is likely
a proportion of full-length PGRN derived from GRN
R493X−/− KI PTC readthrough would possess a missense
mutation at codon 493. Therefore, it was important to
assess the functionality of PGRN produced by PTC read-
through, through its ability to rescue known cellular
FTLD-GRN and NCL phenotypes.
Lysosomal maturation defects have recently been dem-
onstrated as one of the earliest disease phenotypes that
arise in mice null for Grn [15, 17]. Grn−/− mouse brains
upregulate the expression, maturation rate, and catalytic
activity of cathepsin lysosomal proteases (cathepsin D, B,
and L) in an age-dependent manner [17], and this aber-
rant lysosomal phenotype has been previously rescued
in vivo by treating aged Grn−/− mice with AAV-
mediated Grn gene therapy [7]. Moreover, hiPSC-
derived neurons with heterozygous GRN mutations have
been shown to exhibit an increased CTSD maturation
phenotype [16]. We quantified the CTSD levels in aged
(DIV 80) WT and R493X−/− KI hiPSC-derived cortical
neurons and observed significantly increased expression
of the mature form of CTSD in vehicle-treated R493X−/−
KI neurons compared with WT neurons (Fig. 7a, b).
Treating WT neurons with G418, G418 + CDX5–288, or
recombinant human PGRN did not affect mature CTSD
expression levels (Fig. 7a, b). However, treating R493X−/−
KI neurons with G418 and CDX5–288 significantly re-
duced mature CTSD levels, thus rescuing their dysregu-
lated lysosomal enzyme phenotype. Importantly, this
effect was also observed in R493X−/− KI neurons treated
with extracellular recombinant human PGRN with a trend
towards reduced mature CTSD levels (Fig. 7a, b). These
findings provide evidence that PGRN expression restored
by PTC-readthrough in R493X−/− KI cortical neurons
(Fig. 3d) is biologically active and functional in vitro.
Intracerebroventricular administration of G418 induces
GRN PTC readthrough in adult AAV mice expressing a
GRN-R493X-V5 construct
Having demonstrated PTC readthrough in disease-
relevant cellular models of FTLD-GRN, we sought to
provide initial proof-of-concept for this approach
in vivo. CNS ICV PTC readthrough induced by G418
has been previously demonstrated in mice harboring an
inducible gene-targeting system driven by the full-length
expression of a nonsense mutant Cre recombinase [32].
We generated AAV particles containing the same GRN-
V5 R493X reading frame used for HEK293 transfections.
Since this plasmid does not contain a reporter gene, to
establish that our AAV injection technique could
achieve an adequate percentage of neuronal transduction
we first tested an AAV9-eGFP-Cre vector and observed
diffuse brain-wide eGFP expression (Fig. S11). Next,
newborn pups (P0) were bilaterally injected ICV with
virus solution and aged to at least 6 weeks to allow for
sufficient blood-brain-barrier maturation before treat-
ment [33]. RIPA-soluble brain lysates from each ICV
treated AAV-GRN-R493X-V5 mouse were probed by for
V5 expression to assess the extent of GRN R493X PTC
readthrough in vivo. No V5 signal was detected in either
the vehicle (n = 6) or CDX5–288 (n = 4) AAV-GRN-
R493X-V5 brains 72 h after ICV injection (Fig. 8a, b). By
contrast, ICV injections with G418 alone (n = 5) or G418
and CDX5–288 (n = 4) induced clear GRN-R493X-V5
PTC readthrough, as shown by the detection of V5 sig-
nal at the molecular weight (MW) of PGRN, using
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automated western analysis (WES) (Fig. 8a, b). G418 sig-
nificantly induced readthrough in AAV-GRN-R493X-V5
mice compared to treatment with vehicle solution (Fig.
8a, b). Though robust V5 levels were detected, co-
treatment of AAV-GRN-R493X-V5 mice with CDX5–
288 did not increase full-length PGRN levels compared
to G418 alone (Fig. 8a, b). Our data indicate that the
aminoglycoside G418 can induce GRN PTC readthrough
in vivo when delivered intraventricularly in an exogen-
ous AAV transgene expression model.
Discussion
In this study, we show that PGRN insufficiency caused
by GRN nonsense mutations can be ameliorated through
PTC readthrough in in vitro and in vivo models of
FTLD-GRN, and that the resultant increase in PGRN re-
verses FTLD-GRN-related lysosomal dysfunction. We
first generated several human expression constructs with
known clinical GRN nonsense mutations, and observed
the most robust PTC readthrough in response to G418
and CDX5–288 enhancer in R418X and R493X mutant
HEK293 cells compared to G418 treatment alone or co-
treatment with other enhancer compounds. To avoid
confounding measures of endogenous PGRN in HEK293
cells, and to ensure the measured PGRN was reflective
of full-length protein produced by readthrough, the
GRN expression constructs bore a C-terminal V5 tag.
The readthrough enhancer compounds are N-
substituted phthalimide derivatives that were identified
in a high throughput screen in combination with sub-
active concentrations of the aminoglycoside paromomy-
cin, and further systematically functionalized to increase
their potency [14]. To verify GRN PTC-readthrough in a
more disease-specific context, we tested the same G418/
enhancer combination in cortical neurons differentiated
from patient-derived iPSCs bearing the GRN nonsense
mutations tested in HEK293 cells. Similar to our results
in HEK293 cells, GRN readthrough and up to 2.5X in-
crease in PGRN/GRNs was observed in neurons with
the R418X (heterozygous) and R493X (homozygous)
nonsense mutations after 72 h exposure to G418 and
CDX5–288 combination treatment. In both HEK293
Fig. 7 GRN PTC readthrough rescues FTLD/NCL lysosomal pathological CSTD maturation phenotype in hiPSC-derived R493X−/− KI cortical
neurons. a DIV 80 WT and R493X−/− KI hiPSC-derived cortical neurons were treated with vehicle solution, G418 alone, G418 in combination with
CDX5–288, and rec. Human PGRN at the indicated concentrations for 72 h. Expression of mature CSTD in treated WT and R493X−/− KI cortical
neuron lysates analyzed by western blotting, using actin as the loading control. b Densitometric quantification of CSTD expression in the
aforementioned cortical neuron lysates normalized to vehicle-treated WT levels. n = 3–6 independent cultures; values are shown as mean ± SEM; *
p < 0.05, ** p < 0.01, was determined by one-way ANOVA with Tukey’s multiple comparison test
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cells as well as human neurons we did not observe read-
through in cells bearing the S116X nonsense mutation,
most consistent with less efficient readthrough previ-
ously reported with TAA stop codons [25].
Since the GRN expression constructs in HEK293 cells
bore a C-terminal V5 tag, the resulting PGRN could only
be explained by GRN readthrough yielding full-length
protein. In human neurons we were not able to detect
full-length PGRN, likely due to their lower levels of ex-
pression or rapid processing into smaller granulin pep-
tides (Fig S6, S7). Therefore, we used a commercially
available ELISA kit that detects PGRN at multiple epi-
topes (GRN-1, 3, 5, & 7) to measure general changes in
cortical neuron PGRN expression, precluding discrimin-
ation between the truncated and full-length forms of
PGRN or GRN peptides. In contrast, we showed that full-
length and truncated PGRN are measurable by western
blot in human astrocytes, allowing more precise measure-
ments of PGRN protein of various sizes, including full-
length, truncated forms, and GRN peptides. In response
to G418 and CDX5–288, there is a significant increase in
truncated and likely full-length PGRN in R493X−/− KI as-
trocytes, as well as an increase in GRN peptides 2,3. This
increase reflects a greater than 6-fold increase in GRN
mRNA in response to G418 and CDX5–288 combination
treatment. Increased mRNA is characteristic of escape
from NMD, in which nonsense mutant mRNA undergoes
its pioneering round of full-length translation without stal-
ling at its PTC. This process is thought to be regulated by
the degree of PTC readthrough, and only a minor increase
in translation beyond a proposed 0.5% threshold would be
sufficient for substantial NMD inhibition and increased
translation as shown in yeast [34]. G418 has been previ-
ously demonstrated to inhibit NMD through this
readthrough-dependent mechanism [35]. Stabilization of
R493X mutant GRN mRNA leads to accumulation of
truncated protein, which was evident in R493X−/− KI as-
trocytes treated with both G418 alone and CDX5–288
combination. Moreover, the increase in ~ 70 kDa PGRN
signal detected in the R493X−/− KI astrocytes was accom-
panied by a faint slightly higher MW band (Fig. 4a) that
we suspected may represent full-length PGRN. Given that
both WT and R493X−/− KI astrocytes rapidly and effi-
ciently process PGRN into individual GRN peptides it is
likely that the majority of PTC readthrough-derived full-
length PGRN would also be cleaved into GRNs, thus mak-
ing full-length PGRN particularly difficult to detect. This
hypothesis is supported by the observed increase in full-
length PGRN in R493X−/− KI astrocytes in response to
readthrough treatment, when the major lysosomal PGRN
Fig. 8 Induction of PTC readthrough in the mouse brain expressing R493X GRN-V5. a 6-week-old AAV-GRN-R493X-V5 mice were stereotactically
injected ICV with either vehicle solution, G418, CDX5–288, or a combination of G418 + CDX5–288 and sacrificed after 72 h. Whole-brain RIPA-
soluble protein extracts were subjected to automated capillary electrophoresis western analysis. Full-length PGRN was detected with a V5 antibody
and actin was measured in brain lysates as a loading control. b Chemiluminescence quantification of automated capillary electrophoresis western
analysis V5 detection normalized to actin. Values are shown as mean ± SEM; * p < 0.05 was determined by one-way ANOVA with Tukey’s multiple
comparison test
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processing enzyme cathepsin L is inhibited. These results
suggest that the increase in intracellular PGRN/GRNs in
R493X−/− KI cortical neurons likely reflects a mixture of
both truncated and full-length PGRN.
Interestingly, treating R493X−/− KI cortical neurons
with G418 and CDX5–288 combination rescued aber-
rant lysosomal function in these cells, reducing mature
CTSD levels back to WT levels. Recent studies have dis-
covered a physical interaction between PGRNs C-
terminus and CTSD [16, 36, 37]. Despite some conflict-
ing reports [17], the growing consensus is that PGRN
binds to the pro-form of CTSD promoting its maturation,
thus increasing its enzymatic activity [16, 38]. However,
this hypothesis is contradicted by the observation that ma-
ture CSTD is upregulated in Grn−/− mice brains/microglia
and can be rescued with the addition of exogenous mouse
recombinant Pgrn [7, 39]. Nevertheless, our results sug-
gest that PGRN generated by PTC RT can perform bio-
logical functions, and provides supplementary validation
for at least a portion of the readthrough derived neuronal
PGRN being full-length. It has also been recently demon-
strated that the truncated PGRN R493X protein retains
some of its biological properties, such as lysosomal
localization and an ability to suppress a proinflammatory
immune response in Grn−/− mice bone marrow-derived
macrophage cultures [40]. Therefore, we cannot rule out a
contribution of truncated PGRN in the correction of this
excess mature CTSD phenotype.
Unexpectedly, G418 induced accumulation of WT en-
dogenous intracellular PGRN in all of our in vitro models.
Given that G418 increases WT PGRN levels, it was difficult
to prove that PTC readthrough was responsible for the ele-
vated PGRN expression detected in heterozygous R418X+/−
cortical neurons, as any increase in PGRN could be attribut-
able to either increased expression from the WT allele or
PTC-readthrough of the nonsense mutant allele. This pro-
vided the rationale for developing a homozygous R493X−/−
KI line to address this issue and establish that at least a por-
tion of the increased PGRN expression we observed in
R418X+/− neurons was likely reflective of PTC readthrough.
GRN expression analysis in WT cortical neurons and astro-
cytes treated with G418 confirmed that the increase in intra-
cellular PGRN is not due to an accumulation of GRN
mRNA, suggesting the mechanism is post translational in
nature. The G418-mediated intracellular PGRN increase in
WT neurons and astrocytes does not result in corresponding
accumulation of PGRN in culture media, implying that
G418 may interfere with the PGRN secretory pathway. In
R493X mutant astrocytes, treatment with G418 with or with-
out enhancer compound resulted in a more pronounced in-
crease in both mRNA and PGRN than that observed in
neurons. We cannot fully rule out G418-related mechanisms
other than readthrough that may uniquely impact PGRN
processing in astrocytes. Although G418 is not suitable for
human use, further studies would be needed to better under-
stand a possible role for G418 in PGRN processing.
As G418 and other aminoglycosides do not readily
cross the blood-brain barrier, we sought to determine
whether ICV administration of compounds could be a viable
strategy for widespread brain exposure and readthrough. In-
deed, our results provide proof-of-concept that a single ICV
injection of G418 can induce robust PTC readthrough in an
AAV-GRN-R493X-V5 mouse model in only 72 h. Given the
experimental complexity associated with drug screening in
AAV models, which likely contributed to relatively high
variability seen in injected mice, we were unable to identify
an optimal dosage of enhancer compound to treat in com-
bination with G418. The newly available R493X KI mouse
model of FTLD-GRN/NCL [40] may be a better and more
consistent model to further explore the optimal in vivo
doses of both G418 and enhancer compounds.
To our knowledge this is the first report demonstrating
the ability of nonsense mutation readthrough to enhance
PGRN expression in FTLD-GRN patient-derived neurons/
astrocytes, as well as in an in vivo AAV mouse model ex-
pressing a human GRN construct with the most common
R493X pathogenic mutation. Since the submission of our
work, another group have demonstrated GRN read-
through in response to G418 in a mouse neuroblastoma
cell line (N2A) overexpressing a human GRN R493X con-
struct [41]. This preliminary report further validates our
current results in human cell lines. Importantly, there are
several known clinical limitations with the use of amino-
glycosides as a potential therapeutic [42–44]. While G418
is not suitable for long-term human consumption, our
work shows that PTC readthrough is a promising strategy
in FTLD-GRN, and highlights the importance of ongoing
and future efforts to find novel readthrough compounds
more suitable for human use. Our work also shows a nar-
row therapeutic window, such as that seen with gentami-
cin, can be mitigated through enhancer compounds.
Future studies are needed to further explore whether PTC
readthrough induced PGRN rescue is sufficient to surpass
the therapeutic threshold required to disrupt or slow
down FTLD-GRN pathogenesis.
Conclusions
In summary, we show that gentamicin G418 increases
PGRN through PTC readthrough in cellular models of
FTLD due to a pathogenic progranulin nonsense mutation.
The enhancer compound CDX5–288 potentiates the read-
through effects of G418 in vitro and increases PGRN over
G418 treatment alone. We further show that increased pro-
granulin through PTC readthrough ameliorates lysosomal
dysfunction in R493X−/− KI neurons, showing a functional
impact of raised PGRN. Intracerebroventricular administra-
tion of G418 in mice expressing the tagged human R493X
nonsense mutation achieves in vivo PTC readthrough, and
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a single drug injection increases whole brain PGRN levels.
Taken together, our findings suggest that PTC readthrough
may be a potential therapeutic strategy for a subset of pa-
tients with FTLD bearing a GRN nonsense mutation.
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